Amylyx Pharmaceuticals 경영진
경영진 기준 점검 4/4
Amylyx Pharmaceuticals CEO는 Josh Cohen, Jan2013 에 임명되었습니다 의 임기는 13.33 년입니다. 총 연간 보상은 $2.72M, 25.2% 급여 및 74.8% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $42.34M 가치에 해당하는 회사 주식의 2.8% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 5.3 년과 5.3 년입니다.
핵심 정보
Josh Cohen
최고경영자
US$2.7m
총 보수
| CEO 급여 비율 | 25.23% |
| CEO 재임 기간 | 13.3yrs |
| CEO 지분 보유율 | 2.8% |
| 경영진 평균 재임 기간 | 5.3yrs |
| 이사회 평균 재임 기간 | 5.3yrs |
최근 경영진 업데이트
Recent updates
새로운 내러티브 • Apr 02
Bullish View That Future PBH Therapy Breakthrough Will Underpin Long Term Upside Potential
Catalysts About Amylyx Pharmaceuticals Amylyx Pharmaceuticals focuses on developing therapies for endocrine and neurodegenerative conditions, with a current emphasis on post bariatric hypoglycemia and ALS. What are the underlying business or industry changes driving this perspective?
새로운 내러티브 • Mar 19
Post Bariatric Hypoglycemia Setbacks Will Pressure Earnings Before Long Term Endocrine Potential Emerges
Catalysts About Amylyx Pharmaceuticals Amylyx Pharmaceuticals is a biopharmaceutical company focused on treatments for endocrine conditions such as post bariatric hypoglycemia and neurodegenerative diseases including ALS and Wolfram syndrome. What are the underlying business or industry changes driving this perspective?
새로운 내러티브 • Mar 05
PBH Franchise And Neurodegeneration Pipeline Will Support A Stronger Future Business Model
Catalysts About Amylyx Pharmaceuticals Amylyx Pharmaceuticals is a biopharmaceutical company focused on developing treatments for endocrine disorders and neurodegenerative diseases. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Jan 27
Amylyx Pharmaceuticals: Back From The Dead
Summary Amylyx Pharmaceuticals has rebounded sharply since its nadir in 2024, driven by the acquisition of avexitide and renewed pipeline optimism. Avexitide targets post-bariatric hypoglycemia, an underserved market with no approved therapies and significant unmet need. Street sentiment is bullish on AMLX, but current valuation appears fair given projected sales and patient penetration. An analysis around Amylyx Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking Alpha분석 기사 • Sep 01
Here's Why We're A Bit Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Amylyx Pharmaceuticals...분석 기사 • May 10
Can Amylyx Pharmaceuticals (NASDAQ:AMLX) Afford To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...분석 기사 • Apr 03
Optimistic Investors Push Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Up 26% But Growth Is Lacking
Those holding Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) shares would be relieved that the share price has rebounded...
새로운 내러티브 • Apr 01
Avexitide Launch In 2027 Will Strengthen Our Pipeline
Strategic developments in the pipeline and collaborations aim to address unmet medical needs and present long-term revenue growth opportunities.Seeking Alpha • Feb 24
Amylyx Pharmaceuticals: Lots Of Setbacks, Some Chances Of Recovery
Summary AMLX has had major setbacks in its lifecycle, including the voluntary withdrawal of an approved drug. The company purchased late-stage assets from a bankrupt company and are running them through trials. Considerable risks remain as to the market, and whether AMLX can overcome its streak of bad luck. Read the full article on Seeking Alpha분석 기사 • Dec 19
Little Excitement Around Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Revenues As Shares Take 26% Pounding
The Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) share price has softened a substantial 26% over the previous 30 days...분석 기사 • Dec 10
Is Amylyx Pharmaceuticals (NASDAQ:AMLX) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Seeking Alpha • Nov 25
Amylyx: AMX0035 PSP Data In Mid-2025 Is Just One Program Moving Along
Summary The company reported positive results from the phase 2 HELIOS study of AMX0035 for Wolfram Syndrome, setting up initiation of a potential phase 3 trial in 2025. An interim analysis of the phase 2b/3 ORION trial for Progressive Supranuclear Palsy is expected in mid-2025, determining the program's future. Financially, Amylyx has $234.4 million in cash, enough to fund operations into 2026, but may need to raise additional funds in 2025. Avexitide, an acquired GLP-1 receptor antagonist for patients with post-bariatric hypoglycemia, is expected to start a phase 3 study in Q1 of 2025, with data expected in 2026. Read the full article on Seeking Alpha분석 기사 • Nov 04
There's No Escaping Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Muted Revenues Despite A 81% Share Price Rise
Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) shares have continued their recent momentum with a 81% gain in the last...분석 기사 • Sep 18
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry
Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) shares have continued their recent momentum with a 37% gain in the last...Seeking Alpha • Jun 25
Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition
Summary Amylyx Pharmaceuticals, Inc.'s relyvrio for ALS was voluntarily delisted in the U.S. and Canada, but has a chance to target this indication with the advancement of AMX0114; IND filing and trial initiation expected in 2024. Full data from the phase 2 HELIOS trial, using AMX0035 to treat patients with Wolfram syndrome, is expected Fall of 2024. Interim analysis from phase 3 ORION study, using AMX0035 to treat patients with progressive supranuclear palsy, expected mid-2025. The company could possibly acquire rights to phase 3 ready GLP-1 asset Avexitide; This depends upon meeting certain conditions under this agreement, including a favorable ruling from the Texas Bankruptcy Court. Read the full article on Seeking Alpha분석 기사 • Apr 25
Lacklustre Performance Is Driving Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 31% Price Drop
Unfortunately for some shareholders, the Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) share price has dived 31% in the...분석 기사 • Mar 12
Analysts Just Shaved Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Forecasts Dramatically
Today is shaping up negative for Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) shareholders, with the analysts...Seeking Alpha • Mar 09
An ALS Drug Fails Again
Summary The ALS drug (Relyvrio) had been put through a Phase II trial by its developer, Amylyx. Amylyx was already working on a Phase III trial, and they committed to withdrawing the drug if this trial showed no efficacy. Just like with the recent approvals in Alzheimer's, the patient advocacy groups took victory laps after Relyvrio was approved, and they were a big part of the pressure that made the FDA reverse its initial correct decision. Read the full article on Seeking AlphaSeeking Alpha • Feb 23
Amylyx Pharmaceuticals: Q4 Earnings Insight And PHOENIX Trial Implications
Summary Amylyx Pharmaceuticals' stock has rebounded by 50% since a rating downgrade in November, reflecting investor relief after Q4 earnings were in line with expectations. The company provided an earlier timeline for Phase 3 PHOENIX trial data, which will impact the market prospects of its ALS drug, Relyvrio. Positive PHOENIX trial data could boost Amylyx's stock by 200%, while negative data could send it down by at least 50%. Read the full article on Seeking Alpha분석 기사 • Feb 23
Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 27% Price Boost Is Out Of Tune With Revenues
Despite an already strong run, Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) shares have been powering on, with a gain...CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$150m |
| Dec 31 2025 | US$3m | US$686k | -US$145m |
| Sep 30 2025 | n/a | n/a | -US$149m |
| Jun 30 2025 | n/a | n/a | -US$188m |
| Mar 31 2025 | n/a | n/a | -US$219m |
| Dec 31 2024 | US$6m | US$686k | -US$302m |
| Sep 30 2024 | n/a | n/a | -US$259m |
| Jun 30 2024 | n/a | n/a | -US$166m |
| Mar 31 2024 | n/a | n/a | -US$71m |
| Dec 31 2023 | US$7m | US$621k | US$49m |
| Sep 30 2023 | n/a | n/a | US$2m |
| Jun 30 2023 | n/a | n/a | -US$73m |
| Mar 31 2023 | n/a | n/a | -US$149m |
| Dec 31 2022 | US$7m | US$539k | -US$198m |
| Sep 30 2022 | n/a | n/a | -US$184m |
| Jun 30 2022 | n/a | n/a | -US$153m |
| Mar 31 2022 | n/a | n/a | -US$121m |
| Dec 31 2021 | US$1m | US$418k | -US$88m |
| Sep 30 2021 | n/a | n/a | -US$68m |
| Dec 31 2020 | US$671k | US$370k | -US$42m |
보상 대 시장: Josh의 총 보수(USD2.72M)는 US 시장에서 비슷한 규모 기업의 평균(USD5.48M)보다 낮습니다.
보상과 수익: Josh의 보상은 지난 1년 동안 회사 실적과 일치했습니다.
CEO
Josh Cohen (33 yo)
13.3yrs
재임 기간
US$2,719,807
보수
Mr. Joshua B. Cohen also known as Josh, co-founded Amylyx Pharmaceuticals, Inc. in 2013 and has been its Co-Chief Executive Officer and Director since January 2014. Mr. Cohen served as Chairman of the Boar...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Co-Founder | 13.3yrs | US$2.72m | 2.8% $ 42.3m | |
| Co-CEO & Director | 13.3yrs | US$2.72m | 2.8% $ 42.3m | |
| Chief Financial Officer | 5.3yrs | US$1.38m | 0.19% $ 2.9m | |
| Chief Medical Officer | 2.5yrs | US$1.57m | 0.080% $ 1.2m | |
| Chief Technical Operations Officer | no data | 데이터 없음 | 데이터 없음 | |
| Head of Investor Relations & Communications | no data | 데이터 없음 | 데이터 없음 | |
| Chief Legal Officer & General Counsel | 4.3yrs | US$2.30m | 0.053% $ 803.5k | |
| Chief Human Resources Officer | 2.3yrs | 데이터 없음 | 데이터 없음 | |
| Global Head of Regulatory Affairs | 5.8yrs | 데이터 없음 | 데이터 없음 | |
| VP & Head of Global Medical Affairs | 6yrs | 데이터 없음 | 데이터 없음 | |
| Head of Global Medical Strategy & Communications | no data | 데이터 없음 | 데이터 없음 | |
| Chief Commercial Officer | 1.3yrs | 데이터 없음 | 데이터 없음 |
5.3yrs
평균 재임 기간
53yo
평균 나이
경험이 풍부한 관리: AMLX의 경영진은 노련하고 경험이 풍부합니다(평균 재임 5.3 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Co-Founder | 12.3yrs | US$2.72m | 2.8% $ 42.3m | |
| Co-CEO & Director | 12.3yrs | US$2.72m | 2.8% $ 42.3m | |
| Special Advisor & Member of Advisory Board | 5.3yrs | US$51.24k | 데이터 없음 | |
| Independent Chairman of the Board | 11.3yrs | US$218.58k | 0.73% $ 11.1m | |
| Chairman of The Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 3.2yrs | US$161.08k | 0.057% $ 858.8k | |
| Independent Director | 4.9yrs | US$173.58k | 0.0045% $ 68.1k | |
| Independent Director | 2.2yrs | US$166.08k | 0.0090% $ 136.0k | |
| Independent Director | 5.2yrs | US$168.58k | 0.0036% $ 53.7k |
5.3yrs
평균 재임 기간
64yo
평균 나이
경험이 풍부한 이사회: AMLX의 이사회는 경험이 있음으로 간주됩니다(평균 재임 5.3 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/21 05:11 |
| 종가 | 2026/05/21 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Amylyx Pharmaceuticals, Inc.는 13명의 분석가가 다루고 있습니다. 이 중 10명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Christopher Chen | Baird |
| null null | Baird |
| Joel Beatty | Baird |